What is the fair value of Cell MedX Corp (OTC-STME) stock?

The current fair value estimate for Cell MedX Corp (OTC-STME) is $0.27. This implies an estimated upside of 23.7% versus the current market price.

Is Cell MedX Corp (OTC-STME) undervalued or overvalued?

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 23.7% versus the current market price.

How is the financial health of Cell MedX Corp?

The current financial health read for Cell MedX Corp (OTC-STME) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

When is Cell MedX Corp's next earnings date?

The next earnings date currently listed for Cell MedX Corp (OTC-STME) is October 28, 2026.

Does Cell MedX Corp (OTC-STME) pay dividends?

The latest available data indicates no current dividend yield for Cell MedX Corp (OTC-STME).

What is the market capitalization of Cell MedX Corp?

The current market capitalization listed for Cell MedX Corp is 4.651 M.

What is the enterprise value of Cell MedX Corp?

The current enterprise value listed for Cell MedX Corp is 5.471 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

What is the ticker symbol for Cell MedX Corp?

The ticker symbol for Cell MedX Corp is OTC-STME, and the stock is listed on OTC Markets.

Where is Cell MedX Corp (OTC-STME) listed?

Cell MedX Corp (OTC-STME) is listed on OTC Markets.

What is the debt-to-total-capital ratio for Cell MedX Corp?

The current debt-to-total-capital ratio listed for Cell MedX Corp is 15.0%, which helps investors evaluate the company’s financing structure and leverage profile.

What is the free float for Cell MedX Corp?

The free float listed for Cell MedX Corp is 28.1%. Free float helps investors understand how much of the share base is available for public trading.

Cell MedX Corp (STME) Fair Value & Stock Analysis

Cell MedX Corp (STME)

Cell MedX Corp, formerly known as StimCell Energetics Inc., is a common stock listing on OTC Markets in the healthcare sector. The company, incorporated in 2010 and headquartered in Vancouver, Canada, is associated with a biotech business focused on developing, manufacturing, and commercializing therapeutic and non-therapeutic products. Its stated areas of interest include diabetes, Parkinson’s disease, high blood pressure, neuropathy, and kidney-related functions in the United States. The company’s product line includes the eBalance Pro System for use by healthcare practitioners in clinical settings and the eBalance Home System for home use, both designed around the eBalance Console and its pre-programmed microcurrent algorithms for wellness, pain management, and dual use. The systems are also described as providing temporary relief for pain in the shoulder, waist, back, neck, arms, and legs.

Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.

Ticker	Fair Value	Fair Value Upside/Downside	Fair Value Rating	Analyst Price Target	Analyst Target Upside/Downside	Overall Financial Health	Dividend Yield	Next Earnings Date	Market Cap	Enterprise Value	Total Debt / Total Capital	Free Float / Shares Outstanding	Altman Z-Score	Free Cash Flow / Net Income
OTC-STME	$0.27	23.7% Upside	Undervalued	Not available	Not available	Weak	0.0%	October 28, 2026	4.651 M	5.471 M	15.0%	28.1%	-681.9	34.9%